
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-42373

Gelteq Limited
(Registrant's Name)

Level 19
644 Chapel Street
South Yarra VIC, 3141
Australia
(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On December 9, 2025, Gelteq Limited (the “Company”) will be providing a virtual presentation hosted by Investor Summit to certain private investors. A copy of this presentation is furnished as Exhibit 99.1 to this Current Report on Form 6-K.

The foregoing (including Exhibit 99.1) will not be deemed to be filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 6-K and the exhibits hereto contain “forward-looking statements” for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that represent the Company’s beliefs, projections and predictions about future events. All statements other than statements of historical fact are “forward-looking statements,” including any projections of earnings, revenue or other financial items, any statements of the plans, strategies and objectives of management for future operations, any statements concerning proposed new projects or other developments, any statements regarding future economic conditions or performance, any statements of management’s beliefs, goals, strategies, intentions and objectives, and any statements of assumptions underlying any of the foregoing. Words such as “may”, “will”, “should”, “could”, “would”, “predicts”, “potential”, “continue”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates” and similar expressions, as well as statements in the future tense, identify forward-looking statements.

These statements are necessarily subjective and involve known and unknown risks, uncertainties and other important factors that could cause the Company’s actual results, performance or achievements, or industry results, to differ materially from any future results, performance or achievements described in or implied by such statements. Actual results may differ materially from expected results described in the Company’s forward-looking statements, including with respect to correct measurement and identification of factors affecting the Company’s business or the extent of their likely impact, and the accuracy and completeness of the publicly available information with respect to the factors upon which the Company’s business strategy is based or the success of the Company’s business.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of whether, or the times by which, the Company’s performance or results may be achieved. Forward-looking statements are based on information available at the time those statements are made and management’s belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Financial Statements and Exhibits.

The following exhibits are being filed herewith:

Exhibit Number	Description
99.1	Investor Presentation, dated December 9, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Gelteq Limited

By: /s/ Nathan Givoni
Name: Nathan Givoni
Title: Chief Executive Officer

Date: December 9, 2025



**The Next Evolution in Oral Drug &
Nutrient Delivery**

INVESTOR OVERVIEW

DECEMBER 2025

© Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

FORWARD LOOKING STATEMENTS



Certain statements in this presentation may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.



GELTEQ (NASDAQ: GELS) OVERVIEW



A global clinical and science based company that has developed a novel drug delivery platform in an ingestible gel form

Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners

Founded in 2017 in Melbourne, Australia, **the company emerged from its founders' work as a dietitian, aiming to improve patient compliance** with an easy to swallow and enjoyable delivery format for medications and nutritional supplements

GELTEQ - COMPANY HIGHLIGHTS



- Innovative drug and nutrient delivery platform that is market ready
- Portfolio of nutraceutical products already developed and sales ready
- Gelteq holds multiple patent families that cover a range of applications for our proprietary gel technology
- Pilot nutraceutical orders recently delivered in China, USA and Australia
- Diverse API pipeline available for R&D and licensing partnerships



RESEARCH AND VALIDATION PARTNER



Engaged Monash University's Medicines Manufacturing Innovation Centre (MMIC) to both verify and test our scientific methodologies.

Monash University is a global leader in Pharmaceutical Science

- #4 Pharmacy and Pharmacology QS Rankings 2025 (Global)*

Gelteq's scientist team is based in Monash Innovation Labs which is a growth and development ecosystem within Monash University.



*<https://www.topuniversities.com/university-subject-rankings/pharmacy-pharmacology>

© Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

MISSION STATEMENT




To improve the lives of humans and animals by making drug and nutraceutical products more accessible and easier to consume



Confidential

MEDICATION COMPLIANCE IS A UNIVERSAL PROBLEM



INDUSTRY CHALLENGES



Challenges that pharmaceutical & supplement companies are facing

- ▶ **Pill Aversion and Swallowing issues**
*~40% of consumers struggle with swallowing supplements**
- ▶ **Patent lifecycle pressures as drug patents expire**
*Bringing a 90% revenue drop when generics arrive***
- ▶ **Crowded markets**
With limited options for differentiated delivery formats
- ▶ **Convenience**
Consumers are demanding new, novel and convenient formats
- ▶ **Inability to hold large dosages**
Available existing formats such as gummies, pills and capsules can't hold large dosages
- ▶ **Poor adherence**
Low medication adherence means less intake and poorer health outcomes



*McCloskey, A.P., Penson, P.E., Tse, Y., Abdelhafiz, M.A., Ahmed, S.N. and Lim, E.J., 2022. Identifying and addressing pill aversion in adults without physiological-related dysphagia: A narrative review. *British Journal of Clinical Pharmacology*, 88(12), pp.5128-5148.

**Rumore, M.M. and Vogenberg, F.R., 2016. Biosimilars: still not quite ready for prime time. *Pharmacy and Therapeutics*, 41(6), p.366.


INDUSTRY CHALLENGES



The oral delivery of oil-soluble (lipophilic) or insoluble compounds are a major challenge for pharmaceutical companies.

40–60% of marketed drugs and up to 90% of discovery candidates are poorly soluble*

Pharmaceutical companies are already investing **~USD\$4-7Bn annually** in technologies that improve delivery of poorly soluble/oily drugs**



*Xie, B., Liu, Y., Li, X., Yang, P. and He, W., 2024. Solubilization techniques used for poorly water-soluble drugs. Acta Pharmaceutica Sinica B, 14(11), pp.4683-4716.

**Solubility Enhancement Excipients Market Size 2025-2032 <https://share.google/DUYk0RWZb7Z9muU3g>

IMAGINE



Imagine if there was an innovative delivery platform that could address the challenges that pharmaceutical and nutraceutical companies are experiencing

THE GELTEQ SOLUTION




Gelteq's patented gel delivery can potentially system solve many of the pharmaceutical and supplement industry's challenges - from poor adherence and pill fatigue to the oral delivery of insoluble ingredients

Our gels can include single or multiple water soluble, fine insoluble **and oil-soluble ingredients**

This can include vitamins, micro and macro nutrients, herbal extracts and active pharmaceutical ingredients (APIs), in a single **shelf-stable gel** with a **uniform texture** and **composition**




- Trial results showed Geltek's innovative technology for water soluble compounds was able to:
 - Improve bioavailability (overall absorption) by over 40%.
 - Provide faster absorption for an API
 - Enhance ingredient absorption which can deliver significantly improved effectiveness of the drug
 - Increase peak concentrations
- The demonstrated bioavailability enhancements by a significant margin provides a strong foundation for applying Geltek's platform across multiple other water-soluble drug classes, with the potential to expand the Company's commercial scope



Graph = Geltek trial results with a water soluble drug and FDA approved product

- Trial results showed Gelteq's innovative technology for oil soluble compounds was able to:
 - Have 300% faster absorption of an API in the first hour which can deliver significantly improved efficiency of the drug
 - Improve bioavailability (overall absorption) by over 20%.
 - Increase peak concentrations
- The enhanced bioavailability and speed of absorption provides a strong foundation for applying Gelteq's platform across multiple other oil-soluble drug classes and addressing a key industry need



Graph = Gelteq trial results with an oil soluble drug and FDA approved product

GELTEQ IS REIMAGINING THE ADMINISTERED DOSE



VS



Gelteq products can be delivered in a well established packaging format that is well adopted in the market... driven by convenience

GELTEQ CAN SOLVE INDUSTRY CHALLENGES



GELTEQ CAN ADDRESSES KEY CHALLENGES PHARMACEUTICAL & SUPPLEMENT COMPANIES ARE FACING

► **Pill Aversion and Swallowing issues**



► **Crowded markets**



► **Inability to hold large dosages**



► **Patent lifecycle pressures as drug patents expire**



► **Convenience**



► **Poor adherence**




*McCloskey, A.P., Penson, P.E., Tse, Y., Abdelhafiz, M.A., Ahmed, S.N. and Lim, E.J., 2022. Identifying and addressing pill aversion in adults without physiological-related dysphagia: A narrative review. *British Journal of Clinical Pharmacology*, 88(12), pp.5128-5148.
**Rumore, M.M. and Vogenberg, F.R., 2016. Biosimilars: still not quite ready for prime time. *Pharmacy and Therapeutics*, 41(6), p.366.

© Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

Gelteq's platform is able to work across the below verticals.
We offer a complete end-to-end service for our licensed partners.




The global pharmaceutical market



Source: Grand View Research. (2025). Pharmaceutical Market (2025 - 2030).

Global nutraceutical/supplement market




Source: Grand View Research. (2025). Nutraceuticals market size, share & trends analysis report, 2025-2030.

MARKET OPPORTUNITY (ANIMAL HEALTH)




Gelteq makes supplement and medication delivery simple and stress-free for pets, pet owners, and veterinarians alike.

Global pet pharmaceutical market



Source: Metatech Insights. (2024). Pet Pharmaceuticals market size, share & forecast 2025-2035(Report ID: MI1173)

Global pet nutraceutical/ supplement market



Source: Grand View Research. (2023). Global pet nutraceuticals market size & outlook, 2023-2030.

© Gelteq Limited 2025. All Rights Reserved. Proprietary & Confidential.

Our strategy is to partner with pharmaceutical and supplement companies to develop, manufacture, and license gel-based products.

Pharmaceutical Companies

We are currently focused on demonstrating the capabilities of our drug delivery platform to prospective pharmaceutical companies who can license our technology for new product sales

Supplement/ Nutraceutical Companies

We are actively engaging with nutraceutical/ supplement companies to license products from our portfolio of gel products. We also develop custom gel formulations tailored to specific needs.

RESEARCH & DEVELOPMENT PIPELINE SNAPSHOT



Human
Animal

		Discovery	Optimisation	Pre Clinical	Clinical	Regulatory Approved
GeRX-761	Pain Management					
GeRX-561	Allergy					
GeRX-461	Diabetes					
GeRx-481	Weight Management					
GeRx-081	Medicinal Cannabis					
GeRX-261	Mental Health					
GeRX-681	Reflux (GERD)					
GeRx-941	Antiparasitic					
GeRX-341	Veterinarian Oncology					



Company

Gelteq
Nathan Givoni, CEO
Monash Innovation Labs
G.60, 22 Alliance Lane
Clayton 3800 Victoria Australia
T: +61 3 9087 3990
ir@gelteq.com
<https://www.gelteq.com>

Investor Relations

Darrow Associates
Matt Kreps
Managing Director
Austin, Texas
United States
T: 214-597-8200
mkreps@darrowir.com